266 related articles for article (PubMed ID: 34105867)
21. Hepatic fibrosis changes in patients with chronic hepatitis C infection who respond to direct-acting antivirals.
Alswat K; Al-Sohaibani F; Khathlan A; Bashmail A; Alanazi M; Kurdi A; Almakadma AH; Al-Hamoudi W
Ann Saudi Med; 2022; 42(2):89-95. PubMed ID: 35380056
[TBL] [Abstract][Full Text] [Related]
22. Fibrosis index based on four factors better predicts advanced fibrosis or cirrhosis than aspartate aminotransferase/platelet ratio index in chronic hepatitis C patients.
Wang CC; Liu CH; Lin CL; Wang PC; Tseng TC; Lin HH; Kao JH
J Formos Med Assoc; 2015 Oct; 114(10):923-8. PubMed ID: 26279173
[TBL] [Abstract][Full Text] [Related]
23. Regression of liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV coinfection.
Lledó GM; Carrasco I; Benítez-Gutiérrez LM; Arias A; Royuela A; Requena S; Cuervas-Mons V; de Mendoza C
AIDS; 2018 Oct; 32(16):2347-2352. PubMed ID: 30096074
[TBL] [Abstract][Full Text] [Related]
24. Indirect serum fibrosis markers in hepatitis C virus (HCV) infection.
Paunovic K; Stojanovic M; Dimitrijevic Z; Paunovic G; Djordjevic V; Konstantinovic L; Kostic S
Med Arch; 2012; 66(4):226-30. PubMed ID: 22919875
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study.
Köksal İ; Yılmaz G; Parlak M; Demirdal T; Kınıklı S; Candan M; Kaya A; Akhan S; Aydoğdu Ö; Turgut H; Gürbüz Y; Dağlı Ö; Gökal AA; Güner R; Kuruüzüm Z; Tarakçı H; Beslen N; Erdoğan S; Özdener F; Study Group TCHC
Turk J Gastroenterol; 2018 Jul; 29(4):464-472. PubMed ID: 30249562
[TBL] [Abstract][Full Text] [Related]
26. Sustained virological response in chronic hepatitis C patients by direct-acting antiviral treatment significantly reduces liver stiffness over 24 weeks posttreatment.
Sirinawasatien A; Supawan P
Medicine (Baltimore); 2024 May; 103(19):e38096. PubMed ID: 38728473
[TBL] [Abstract][Full Text] [Related]
27. Longitudinal assessment of hepatic fibrosis in responders to direct-acting antivirals for recurrent hepatitis C after liver transplantation using noninvasive methods.
Omar H; Said M; Eletreby R; Mehrez M; Bassam M; Abdellatif Z; Hosny A; Megawer S; El Amir M; Yosry A
Clin Transplant; 2018 Aug; 32(8):e13334. PubMed ID: 29935046
[TBL] [Abstract][Full Text] [Related]
28. M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals.
Saleh SA; Salama MM; Alhusseini MM; Mohamed GA
World J Gastroenterol; 2020 Jun; 26(21):2864-2876. PubMed ID: 32550761
[TBL] [Abstract][Full Text] [Related]
29. Noninvasive Assessment of Fibrosis Regression after Direct-acting Antiviral Treatment in Hepatitis C Virus Patients.
Davidov Y; Kleinbaum Y; Inbar Y; Cohen-Ezra O; Veitsman E; Weiss P; Likhter M; Berdichevski T; Katsherginsky S; Hassid A; Tsaraf K; Silverberg D; Ben Ari Z
Isr Med Assoc J; 2021 Dec; 23(12):794-800. PubMed ID: 34954919
[TBL] [Abstract][Full Text] [Related]
30. Improvement of liver stiffness measurement, acoustic radiation force impulse measurements, and noninvasive fibrosis markers after direct-acting antivirals for hepatitis C virus G4 recurrence post living donor liver transplantation: Egyptian cohort.
Alem SA; Said M; Anwar I; Abdellatif Z; Elbaz T; Eletreby R; AbouElKhair M; El-Serafy M; Mogawer S; El-Amir M; El-Shazly M; Hosny A; Yosry A
J Med Virol; 2018 Sep; 90(9):1508-1515. PubMed ID: 29718546
[TBL] [Abstract][Full Text] [Related]
31. Real life application of FIB-4 & APRI during mass treatment of HCV genotype 4 with directly acting anti-viral agents in Egyptian patients, an observational study.
Said M; Soliman Z; Daebes H; M El-Nahaas S; El-Serafy M
Expert Rev Gastroenterol Hepatol; 2019 Dec; 13(12):1189-1195. PubMed ID: 31702417
[No Abstract] [Full Text] [Related]
32. [The diagnostic potential of Golgi protein 73 for cirrhosis in patients with chronic hepatitis C].
Wang PF; Liu SH; Qian XJ; Zhai XW; Wen XJ; Yao MJ; Zhao FM; Lu F
Zhonghua Gan Zang Bing Za Zhi; 2022 Aug; 30(8):879-884. PubMed ID: 36207945
[No Abstract] [Full Text] [Related]
33. Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression?
Kronfli N; Young J; Wang S; Cox J; Walmsley S; Hull M; Cooper C; Martel-Laferriere V; Wong A; Pick N; Klein MB;
Clin Infect Dis; 2021 Aug; 73(3):468-477. PubMed ID: 32504083
[TBL] [Abstract][Full Text] [Related]
34. Fibrosis scores that can be used in follow-up of after direct-acting antiviral treatment: APRI, FIB-4, King score and GUCI.
Tahtasakal CA; Oncul A; Sevgi DY; Demirbas D; Gunduz A; Dokmetas I
Eur J Gastroenterol Hepatol; 2022 Mar; 34(3):308-315. PubMed ID: 34091480
[TBL] [Abstract][Full Text] [Related]
35. Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response.
Tada T; Kumada T; Toyoda H; Mizuno K; Sone Y; Kataoka S; Hashinokuchi S
J Gastroenterol Hepatol; 2017 Dec; 32(12):1982-1988. PubMed ID: 28299813
[TBL] [Abstract][Full Text] [Related]
36. FibroScan, APRI, FIB4, and GUCI: Role in prediction of fibrosis and response to therapy in Egyptian patients with HCV infection.
Yosry A; Fouad R; Alem SA; Elsharkawy A; El-Sayed M; Asem N; Hassan E; Ismail A; Esmat G
Arab J Gastroenterol; 2016 Jun; 17(2):78-83. PubMed ID: 27353055
[TBL] [Abstract][Full Text] [Related]
37. Comparison of chitinase-3-like protein 1, aspartate aminotransferase-to-platelet ratio index, and fibrosis-4 index with shear-wave elastography.
Mushtaq S; Ghani E; Azam K; Hussain T
Eur J Gastroenterol Hepatol; 2019 Mar; 31(3):357-362. PubMed ID: 30431458
[TBL] [Abstract][Full Text] [Related]
38. Effects of HCV Clearance with Direct-Acting Antivirals (DAAs) on Liver Stiffness, Liver Fibrosis Stage and Metabolic/Cellular Parameters.
Ferreira J; Bicho M; Serejo F
Viruses; 2024 Feb; 16(3):. PubMed ID: 38543737
[TBL] [Abstract][Full Text] [Related]
39. Long-term evolution in liver fibrosis and immune profile after direct-acting antivirals therapy in hepatitis C virus-human immunodeficiency virus co-infected patients.
Laguno M; Martínez-Rebollar M; Casanova M; de Lazzari E; González-Cordón A; Torres B; Inciarte A; Mora L; Ugarte A; Ambrosioni J; Blanco JL; Martínez E; Mallolas J
Clin Microbiol Infect; 2022 Apr; 28(4):610.e1-610.e7. PubMed ID: 34464735
[TBL] [Abstract][Full Text] [Related]
40. Exploring the Diagnostic Potential of Serum Golgi Protein 73 for Hepatic Necroinflammation and Fibrosis in Chronic HCV Infection with Different Stages of Liver Injuries.
Qian X; Zheng S; Wang L; Yao M; Guan G; Wen X; Zhang L; Xu Q; Chen X; Zhao J; Duan Z; Lu F
Dis Markers; 2019; 2019():3862024. PubMed ID: 31636735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
